El-Deeb Ibrahim M, Park Byung Sun, Jung Su Jin, Yoo Kyung Ho, Oh Chang-Hyun, Cho Seung Joo, Han Dong Keun, Lee Jae Yeol, Lee So Ha
Department of Biomolecular Science, University of Science and Technology, 113 Gwahangno, Yuseong-gu, Daejeon 305-333, Republic of Korea.
Bioorg Med Chem Lett. 2009 Oct 1;19(19):5622-6. doi: 10.1016/j.bmcl.2009.08.029. Epub 2009 Aug 12.
A series of rationally designed ROS1 tyrosine kinase inhibitors was synthesized and screened. Compound 12b has showed good potency with IC50 value of 209 nM, which is comparable with that of the reference lead compound 1. Molecular modeling studies have been performed, that is, a homology model for ROS1 was built, and the screened inhibitors were docked into its major identified binding site. The docked poses along with the activity data have revealed a group of the essential features for activity. Overall, simplification of the lead compound 1 into compound 12b has maintained the activity, while facilitated the synthetic advantages. A molecular interaction model for ROS1 kinase and inhibitors has been proposed.
合成并筛选了一系列经过合理设计的ROS1酪氨酸激酶抑制剂。化合物12b表现出良好的活性,IC50值为209 nM,与参考先导化合物1相当。已进行分子模拟研究,即构建了ROS1的同源模型,并将筛选出的抑制剂对接至其主要确定的结合位点。对接构象与活性数据揭示了一组活性的基本特征。总体而言,将先导化合物1简化为化合物12b在保持活性的同时,还具有合成优势。提出了ROS1激酶与抑制剂的分子相互作用模型。